Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
तुलना करने के लिए मीट्रिक्स | DVAX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधDVAXपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 82.7x | −4.7x | −0.7x | |
PEG अनुपात | −1.22 | −0.02 | 0.00 | |
क़ीमत/बुक | 2.5x | 1.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 6.5x | 5.9x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 95.5% | 34.8% | 45.9% | |
उचित मूल्य अपसाइड | अनलॉक करें | 11.4% | 7.6% | अनलॉक करें |